Jay Parrish, Ph.D., is Chief Business Officer at Vir Biotechnology. Previously he worked at Gilead Sciences, Inc. on the Corporate Development team, where he was involved in building Gilead’s oncology and infectious disease portfolio. He also worked in Gilead’s Medicinal Chemistry group where his research focused on the discovery of small molecule anti-virals for the treatment of HIV, hepatitis C, and respiratory syncytial viruses. In this role, he was involved with several successful discovery campaigns, including being a co-inventor of ledipasvir (Harvoni®), approved as a cure for hepatitis C genotypes 1, 4–6.
Dr. Parrish holds a B.S. in chemistry from Emory University and a Ph.D. in synthetic organic chemistry from the University of South Florida. He completed a postdoctoral fellowship at the Scripps Research Institute and received an M.B.A. from U.C. Berkeley’s Haas School of Business. He has authored more than 25 peer- reviewed scientific publications and holds more than 20 issued patents. Dr. Parrish continues to serve as a part-time instructor at U.C. Berkeley Extensions and as a venture partner at ARCH Venture Partners.